Fig. 3From: Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancerKaplan-Meier survival analysis. a Median PFS was 2.6 months (95% CI [2.1, 4.0]). b Median OS was 8.3 months (95% CI [5.5, undefined])Back to article page